Effect of gastrointestinal resection on sunitinib exposure in patients with GIST

Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib

(2013) B. D. Furmanski et al.   CLINICAL CANCER RESEARCH

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

(2012) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Histopathology of gastrointestinal stromal tumor

(2011) Markku Miettinen et al.   JOURNAL OF SURGICAL ONCOLOGY

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability

(2010) Kyu-pyo Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib

(2010) Changhoon Yoo et al.   JOURNAL OF CLINICAL ONCOLOGY

pH-Responsive Nanoparticles for Drug Delivery

(2010) Weiwei Gao et al.   MOLECULAR PHARMACEUTICS

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

(2009) Merrill J. Egorin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

(2009) S. Hu et al.   CLINICAL CANCER RESEARCH

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

(2009) B. E. Houk et al.   CLINICAL CANCER RESEARCH

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

(2009) Kuniaki Shirao et al.   INVESTIGATIONAL NEW DRUGS

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

(2009) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY